Advanced Transit Dynamics News

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

Since January 2nd, 2013, a purchase in Johnson & Johnson stock would have created 35.08% in paper wealth for shareholders.

Robert W. Baird's price objective suggests a potential downside of 32.13% from the stock's previous close.

According to the U.S. Department of Justice, the accord, one of the largest healthcare settlements in history, resolved criminal and civil charges over the improper marketing of Risperdal and other medications.

After gains of 30% in 2013, some might think that it's now time to take gains off the table.

With the S&P 500 seemingly hitting all-time highs every couple of weeks, it can prove challenging to dig up "thrift shop stocks" -- in other words, ones that offer tremendous value for money.

Allergan has gained just 5% this year, lagging other pharmaceuticals. Valeant Pharmaceuticals International , for instance, has gained 78% so far in 2013, while Novartis has risen 21%, Johnson & Johnson has advanced 30% and GlaxoSmithKline is up 18%.

Coviden is going back to the well again, buying Given Imaging but a rather uninspiring history of only single-digit operating margin.

Stents have been with us for about 20 years now, and they have definitely made a significant impact in both the treatment of coronary artery disease and the med-tech landscape.

The European Commission has fined pharmaceuticals giants Johnson & Johnson and Novartis a combined $22 million for colluding to delay the entrance of a cheap generic form of a pain killer to the Dutch market.

Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing thesis.

The Wharton School, through its Initiative for Global Environmental Leadership, partnered with Johnson & Johnson to convene healthcare professionals and share best practices for measuring the value of sustainability initiatives.

Clinical trials conducted by Janssen Research & Development, LLC points to evidence that its experimental drug, siltuximab improved symptoms and shrank growths in patients with Castleman disease, a rare blood disorder that causes enlarged lymph nodes.

Although relatively small in size, the two companies' brand lineups are robust. As such, Church & Dwight and Prestige Brands represent two of the most well-rounded investments in the space.

Sovaldi is approved to treat four different strains of hepatitis virus referred to as genotype 1-4.

This week's multi-billion dollar corporate bond offerings from Microsoft, CVS Caremark and Johnson & Johnson pushed the volume of US non-financial investment grade corporate debt to $438.0 billion for year-to-date 2013, a 6% increase compared to a year ago and the strongest year-to-date period on record.

The firm currently has a $61.00 target price on the stock, up from their previous target price of $45.00.

Janis Plostnieks, 80, of Blue Bell, a corporate chemist and executive at Johnson & Johnson for many years, died Friday, Nov. 29, of cancer at Holy Redeemer Hospital.

Johnson & Johnson officials destroyed or misplaced documents related to its vaginal-mesh implants and should be barred from relying on some defenses in planned trials over the devices, patients' lawyers said.

Johnson & Johnson and Bayer's drug Xarelto generated $246 million in sales in the third quarter, while sales of Eliquis from Pfizer and Bristol-Myers Squibb were $41 million for the same period.